Novo Nordisk’s UK unit has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to what was described as “serious
Guidance on the way pharma companies communicate about prescription medicines has been updated in the UK to cover use of social media channels for the first time.